🫀 CAUGHT-CAD Trial Summary 🔬

🔍 Objective: Investigated whether CAC scoring combined with a prevention strategy slows plaque progression in intermediate-risk patients with a family history of CAD.

📊 Key Findings:

✅ LDL Reduction: -51 mg/dL (CAC group) vs. -2 mg/dL (Usual Care) 📉

✅ Slower Plaque Progression: +15.4 mm³ vs. +24.9 mm³ (p=0.009) 🏥

✅ Less Noncalcified Plaque Growth: +5.6 mm³ vs. +15.7 mm³ (p=0.002) 🔬

✅ Regression in High-Risk Plaque (Fibrofatty/Necrotic Core): -0.8 mm³ vs. +4.5 mm³ (p=0.02) 🚀

🎯 Clinical Impact: CAC-informed strategies enhance risk stratification, reduce plaque burden, and support early statin therapy for CAD prevention. 🔄💊